1.34
+0.13(+10.74%)
Currency In USD
| Previous Close | 1.21 |
| Open | 1.26 |
| Day High | 1.4 |
| Day Low | 1.2 |
| 52-Week High | 7.19 |
| 52-Week Low | 1.14 |
| Volume | 755,273 |
| Average Volume | 1.82M |
| Market Cap | 21.78M |
| PE | -0.23 |
| EPS | -5.82 |
| Moving Average 50 Days | 1.63 |
| Moving Average 200 Days | 2.95 |
| Change | 0.13 |
If you invested $1000 in Jasper Therapeutics, Inc. (JSPR) since IPO date, it would be worth $13.65 as of February 19, 2026 at a share price of $1.34. Whereas If you bought $1000 worth of Jasper Therapeutics, Inc. (JSPR) shares 5 years ago, it would be worth $12.79 as of February 19, 2026 at a share price of $1.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
GlobeNewswire Inc.
Jan 07, 2026 9:30 PM GMT
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briq